Australian biotech announces second deal in two days

8 November 2016

An Australian biotech which specializes in the discovery and development of protein-based therapeutics has announced a second deal in as many days – this time by licensing its Alzheimer's disease-specific shark antibodies to a Dutch firm.

AdAlta (ASX: 1AD) has announced a commercialization agreement with Crossbeta Biosciences, a biotechnology company with unique technology for therapeutic and diagnostic use in neurodegenerative disorders.

Financial terms have not been revealed of the deal, which will see Crossbeta being granted an exclusive license to three beta-amyloid oligomer (AßO)-specific shark antibodies, identified under the collaboration signed between the two companies in December 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK